Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of WD-890 for moderate-to-severe plaque psoriasis
CTR20261024Phase 3Active
- Sponsor
- Zhejiang Wenda Pharmaceutical Technology Co., Ltd.
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of WD-890 in plaque psoriasis, sponsored by Zhejiang Wenda Pharmaceutical Technology Co., Ltd.. Started Mar 2026; status: active.
02
Drugs
WD-890
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on CTR20261024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261024.